|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08189 TEDA BIOMEDICAL
Nominal 
0.230 +0.035 (+17.949%) Profitability Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| ROAA (%) | -6.295% | -8.209% | -11.412% | -12.718% | -20.871% |
| ROAE (%) | -33.582% | -32.893% | -34.661% | -28.736% | -36.472% |
| Return on Capital Employed (%) | -23.323% | -23.629% | -27.161% | -24.168% | -41.177% |
Margin Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Gross Profit Margin (%) | 5.368% | 3.646% | 9.573% | 10.936% | 9.755% |
| EBITDA Margin (%) | 0.969% | -1.216% | -6.568% | -10.871% | -18.164% |
| Pre-tax Profit Margin (%) | -3.018% | -5.892% | -9.412% | -13.537% | -24.757% |
| Net Profit Margin (%) | -5.065% | -6.250% | -8.870% | -12.995% | -23.588% |
Liquidity Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Current Ratio (X) | 0.878 X | 0.885 X | 1.087 X | 1.339 X | 1.625 X |
| Quick Ratio (X) | 0.461 X | 0.546 X | 0.695 X | 0.867 X | 1.056 X |
Leverage Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Total Liabilities / Total Assets(%) | 78.706% | 75.934% | 68.251% | 60.515% | 43.216% |
| Total Debt / Total Assets (%) | 27.551% | 30.429% | 25.991% | 13.909% | 10.339% |
| Net Debt / Total Assets (%) | 25.595% | 28.396% | 18.385% | 10.465% | 3.639% |
| Total Debt / Shareholders' Funds (%) | 167.278% | 146.347% | 89.643% | 38.207% | 19.587% |
| Long Term Debt / Shareholders' Funds (%) | 40.630% | 50.254% | 44.862% | 30.383% | 0% |
| Net Debt / Shareholders' Funds (%) | 155.397% | 136.568% | 63.409% | 28.747% | 6.895% |
| Net Cash / (Debt) ($) | (77.623M) | (95.749M) | (63.904M) | (41.118M) | (13.171M) |
| Net Cash / (Debt) per share ($) | (0.041) | (0.051) | (0.034) | (0.022) | (0.007) |
| Total Debt / Capital Employed (%) | 96.670% | 86.262% | 58.072% | 27.517% | 18.208% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Inventory Turnover (Day) | 79.691 Day | 62.855 Day | 70.692 Day | 100.178 Day | 98.394 Day |
| Receivables Turnover (Day) | 18.637 Day | 25.953 Day | 29.105 Day | 51.189 Day | 69.391 Day |
| Payables Turnover (Day) | 16.888 Day | 20.396 Day | 28.081 Day | 31.154 Day | 30.247 Day |
| Remarks: | Real time quote last updated: 08/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -4,123,183 |
| %Change | -63.350% |
| EPS / (LPS) | RMB -0.002 |
| NBV Per Share (¥) | RMB 0.024 |